Q2 2019 Biosyent Inc Earnings Call Transcript

Aug 23, 2019 / NTS GMT
RenéC. Goehrum - BioSyent Inc. - Chairman, CEO & President

Hello, and welcome to the Q2 2019 Results Presentation for BioSyent, Inc. My name is René Goehrum, and I'm the President and CEO of the company.

Before I go into the numbers, I want to tell you about 2 occurrences that came together in the second quarter and would have had a dampening effect on both our top line and bottom line results. So as we've been describing now for some time, there's been some choppiness in our sales of FeraMAX to international customers. These will be customers located outside of Canada.

So our largest customer, and we have got a high concentration with this one customer, has had some challenges with import quotas and availability of currency or currency controls. And so for the second consecutive quarter, we've had no sales to customers outside of Canada for pharmaceutical products, namely FeraMAX.

Also in the quarter, after about a year of dialogue with Health Canada regarding our dossier to get marketing approval for 2 cardiovascular products, we announced in June that we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot